PHOENIX - Marylandian -- Picard Investment Group, Inc. (Picard) announced today the signing of a distribution license agreement of its product with Heka Relief, Inc. (Heka). The product was recently determined to be effective in mitigating the replication of shingles and herpes simplex I and herpes simplex II viruses, which affect approximately 25 to 40 percent of the US population.

"This agreement is the first US license of the product," said John Lorenz, director of the project at Picard and lifelong herbalist and mycologist. "The team at Heka is composed of experienced business professionals, online marketers and experts in the consumer packaged goods industry. This represents the perfect constellation of skilled individuals we were looking for to successfully take this product to market."

More on Marylandian

• Georgia's Magical Nights of Lights Bigger and Brighter for 2026
• Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
• NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
• OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
• FlipTarot Launches Free AI-Powered Tarot Reading Website — 3 Free Readings Daily, No Signup Required

This license goes into effect immediately and will allow Heka to start developing and implementing distribution plans for bringing the product to market in late 2021.

Picard is also in licensing discussions with additional US, Canadian and European corporations.

# # #

About Picard Investment Group, Inc.

Picard Investment Group, Inc. is an Arizona-based private corporation that specializes in developing organic products for the healthcare sector. It is also active in the waste, restoration, water purification and chemical recycling sectors.

About Heka Relief, Inc.

Heka Relief, Inc. is an Arizona-based private corporation that specializes in developing comprehensive go-to-market online strategies and tactical plans for consumer products in the healthcare sector.